HAEM5:Splenic marginal zone lymphoma - Revision history

Madhu.Pantrangi: /* Related Terminology */

2025-09-12T00:53:58Z

Related Terminology

← Older revision		Revision as of 19:53, 11 September 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Splenic marginal zone lymphoma}}		{{DISPLAYTITLE:Splenic marginal zone lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 233:		Line 234:
	!Significance!!Prevalence		!Significance!!Prevalence
	\|-		\|-
	\|~~7q31~~-32\|\|Loss (heterozygous)		\|7q22-36 (a minimal commonly deleted region has been
			mapped to a 3Mb region at 7q32.1-32.2)
			\|Loss (heterozygous)
	\|Unknown; possible haploinsufficiency of IRF5 tumor suppressor<ref>{{Cite journal\|last=Fresquet\|first=Vicente\|last2=Robles\|first2=Eloy F.\|last3=Parker\|first3=Anton\|last4=Martinez-Useros\|first4=Javier\|last5=Mena\|first5=Maria\|last6=Malumbres\|first6=Raquel\|last7=Agirre\|first7=Xabier\|last8=Catarino\|first8=Susana\|last9=Arteta\|first9=David\|date=2012\|title=High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma\|url=http://doi.wiley.com/10.1111/j.1365-2141.2012.09226.x\|journal=British Journal of Haematology\|language=en\|volume=158\|issue=6\|pages=712–726\|doi=10.1111/j.1365-2141.2012.09226.x}}</ref>\|\|26–45%<ref name=":2">{{Cite journal\|last=Salido\|first=Marta\|last2=Baró\|first2=Cristina\|last3=Oscier\|first3=David\|last4=Stamatopoulos\|first4=Kostas\|last5=Dierlamm\|first5=Judith\|last6=Matutes\|first6=Estela\|last7=Traverse-Glehen\|first7=Alexandra\|last8=Berger\|first8=Francoise\|last9=Felman\|first9=Pascale\|date=2010\|title=Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group\|url=https://ashpublications.org/blood/article/116/9/1479/103841/Cytogenetic-aberrations-and-their-prognostic-value\|journal=Blood\|language=en\|volume=116\|issue=9\|pages=1479–1488\|doi=10.1182/blood-2010-02-267476\|issn=0006-4971}}</ref><ref name=":3">{{Cite journal\|last=Baró\|first=Cristina\|last2=Salido\|first2=Marta\|last3=Espinet\|first3=Blanca\|last4=Astier\|first4=Laura\|last5=Domingo\|first5=Alicia\|last6=Granada\|first6=Isabel\|last7=Millà\|first7=Fuensanta\|last8=Carrió\|first8=Ana\|last9=Costa\|first9=Dolors\|date=2008\|title=New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY)\|url=https://linkinghub.elsevier.com/retrieve/pii/S0145212607003505\|journal=Leukemia Research\|language=en\|volume=32\|issue=5\|pages=727–736\|doi=10.1016/j.leukres.2007.09.012}}</ref><ref name=":4">{{Cite journal\|last=Gruszka-Westwood\|first=Alicja M.\|last2=Hamoudi\|first2=Rifat\|last3=Osborne\|first3=Lucy\|last4=Matutes\|first4=Estella\|last5=Catovsky\|first5=Daniel\|date=2003\|title=Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes\|url=http://doi.wiley.com/10.1002/gcc.10142\|journal=Genes, Chromosomes and Cancer\|language=en\|volume=36\|issue=1\|pages=57–69\|doi=10.1002/gcc.10142\|issn=1045-2257}}</ref>		\|Unknown; possible haploinsufficiency of IRF5 tumor suppressor<ref>{{Cite journal\|last=Fresquet\|first=Vicente\|last2=Robles\|first2=Eloy F.\|last3=Parker\|first3=Anton\|last4=Martinez-Useros\|first4=Javier\|last5=Mena\|first5=Maria\|last6=Malumbres\|first6=Raquel\|last7=Agirre\|first7=Xabier\|last8=Catarino\|first8=Susana\|last9=Arteta\|first9=David\|date=2012\|title=High-throughput sequencing analysis of the chromosome 7q32 deletion reveals IRF5 as a potential tumour suppressor in splenic marginal-zone lymphoma\|url=http://doi.wiley.com/10.1111/j.1365-2141.2012.09226.x\|journal=British Journal of Haematology\|language=en\|volume=158\|issue=6\|pages=712–726\|doi=10.1111/j.1365-2141.2012.09226.x}}</ref>\|\|26–45%<ref name=":2">{{Cite journal\|last=Salido\|first=Marta\|last2=Baró\|first2=Cristina\|last3=Oscier\|first3=David\|last4=Stamatopoulos\|first4=Kostas\|last5=Dierlamm\|first5=Judith\|last6=Matutes\|first6=Estela\|last7=Traverse-Glehen\|first7=Alexandra\|last8=Berger\|first8=Francoise\|last9=Felman\|first9=Pascale\|date=2010\|title=Cytogenetic aberrations and their prognostic value in a series of 330 splenic marginal zone B-cell lymphomas: a multicenter study of the Splenic B-Cell Lymphoma Group\|url=https://ashpublications.org/blood/article/116/9/1479/103841/Cytogenetic-aberrations-and-their-prognostic-value\|journal=Blood\|language=en\|volume=116\|issue=9\|pages=1479–1488\|doi=10.1182/blood-2010-02-267476\|issn=0006-4971}}</ref><ref name=":3">{{Cite journal\|last=Baró\|first=Cristina\|last2=Salido\|first2=Marta\|last3=Espinet\|first3=Blanca\|last4=Astier\|first4=Laura\|last5=Domingo\|first5=Alicia\|last6=Granada\|first6=Isabel\|last7=Millà\|first7=Fuensanta\|last8=Carrió\|first8=Ana\|last9=Costa\|first9=Dolors\|date=2008\|title=New chromosomal alterations in a series of 23 splenic marginal zone lymphoma patients revealed by Spectral Karyotyping (SKY)\|url=https://linkinghub.elsevier.com/retrieve/pii/S0145212607003505\|journal=Leukemia Research\|language=en\|volume=32\|issue=5\|pages=727–736\|doi=10.1016/j.leukres.2007.09.012}}</ref><ref name=":4">{{Cite journal\|last=Gruszka-Westwood\|first=Alicja M.\|last2=Hamoudi\|first2=Rifat\|last3=Osborne\|first3=Lucy\|last4=Matutes\|first4=Estella\|last5=Catovsky\|first5=Daniel\|date=2003\|title=Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes\|url=http://doi.wiley.com/10.1002/gcc.10142\|journal=Genes, Chromosomes and Cancer\|language=en\|volume=36\|issue=1\|pages=57–69\|doi=10.1002/gcc.10142\|issn=1045-2257}}</ref>
	\|-		\|-
	\|3/3q\|\|Gain (trisomy)		\|3/3q\|\|Gain (trisomy)
	\|Unknown\|\|15%<ref name=":2" /><ref name=":4" /><ref name=":3" />		\|Unknown\|\|15%<ref name=":2" /><ref name=":4" /><ref name=":3" />
			\|-
			\|17p13(TP53)
			\|Loss
			\|
			\|3%-17%
	\|}		\|}

Bailey.Glen at 17:29, 3 July 2025

2025-07-03T17:29:32Z

← Older revision		Revision as of 12:29, 3 July 2025
Line 34:		Line 34:
	\|}		\|}

	~~==WHO Essential and Desirable Genetic Diagnostic Criteria==~~
	<span style="color:#0070C0">(''Instructions: The table will have the diagnostic criteria from the WHO book <u>autocompleted</u>; remove any <u>non</u>-genetics related criteria. If applicable, add text about other classification'' ''systems that define this entity and specify how the genetics-related criteria differ.'')</span>
	~~{\| class="wikitable"~~
	\|+
	\|WHO Essential Criteria (Genetics)*
	\|
	\|-
	\|WHO Desirable Criteria (Genetics)*
	\|
	\|-
	~~\|Other Classification~~
	\|
	\|}
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==

Bailey.Glen at 21:49, 25 May 2025

2025-05-25T21:49:53Z

← Older revision		Revision as of 16:49, 25 May 2025
Line 190:		Line 190:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Chr #!!~~'''~~Gain, Loss, Amp, LOH~~'''~~!!~~'''~~Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]~~'''~~!!~~'''~~Relevant Gene(s)~~'''~~		!Chr #!!Gain, Loss, Amp, LOH!!Minimal Region Cytoband and/or Genomic Coordinates [Genome Build; Size]!!Relevant Gene(s)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 266:		Line 266:
	!Chromosomal Pattern		!Chromosomal Pattern
	!Molecular Pathogenesis		!Molecular Pathogenesis
	!~~'''~~Prevalence -~~'''~~		!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>		\|<span class="blue-text">EXAMPLE:</span>
Line 310:		Line 310:
	{\| class="wikitable sortable"		{\| class="wikitable sortable"
	\|-		\|-
	!Gene!!~~'''~~Genetic Alteration~~'''~~!!~~'''~~Tumor Suppressor Gene, Oncogene, Other~~'''~~!!~~'''~~Prevalence -~~'''~~		!Gene!!Genetic Alteration!!Tumor Suppressor Gene, Oncogene, Other!!Prevalence -
	~~'''~~Common >20%, Recurrent 5-20% or Rare <5% (Disease)~~'''~~		Common >20%, Recurrent 5-20% or Rare <5% (Disease)
	!~~'''~~Diagnostic, Prognostic, and Therapeutic Significance - D, P, T ~~'''~~		!Diagnostic, Prognostic, and Therapeutic Significance - D, P, T
	!~~'''~~Established Clinical Significance Per Guidelines - Yes or No (Source)~~'''~~		!Established Clinical Significance Per Guidelines - Yes or No (Source)
	!~~'''~~Clinical Relevance Details/Other Notes~~'''~~		!Clinical Relevance Details/Other Notes
	\|-		\|-
	\|<span class="blue-text">EXAMPLE:</span>''EGFR''		\|<span class="blue-text">EXAMPLE:</span>''EGFR''

Bailey.Glen at 20:25, 25 May 2025

2025-05-25T20:25:21Z

← Older revision		Revision as of 15:25, 25 May 2025
Line 49:		Line 49:
	<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].		<nowiki>*</nowiki>Note: These are only the genetic/genomic criteria. Additional diagnostic criteria can be found in the [https://tumourclassification.iarc.who.int/home <u>WHO Classification of Tumours</u>].
	==Related Terminology==		==Related Terminology==
	~~<span style="color:#0070C0">(''Instructions: The table will have the related terminology from the WHO <u>autocompleted</u>.)''</span>~~
	{\| class="wikitable"		{\| class="wikitable"
	\|+		\|+
	\|Acceptable		\|Acceptable
	\|		\|N/A
	\|-		\|-
	\|Not Recommended		\|Not Recommended
	\|		\|Splenic lymphoma with villous lymphocytes
	\|}		\|}

Bailey.Glen at 19:22, 25 May 2025

2025-05-25T19:22:06Z

← Older revision		Revision as of 14:22, 25 May 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Splenic marginal zone lymphoma}}		{{DISPLAYTITLE:Splenic marginal zone lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Jennelleh at 14:30, 15 April 2025

2025-04-15T14:30:04Z

← Older revision		Revision as of 09:30, 15 April 2025
Line 12:		Line 12:
	==Primary Author(s)*==		==Primary Author(s)*==
	Madhu Pantrangi, Weill Cornell Medical Center		Madhu Pantrangi, Weill Cornell Medical Center

	~~Snehal Patel, MD, PhD~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Jennelleh at 14:29, 15 April 2025

2025-04-15T14:29:44Z

← Older revision		Revision as of 09:29, 15 April 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Splenic marginal zone lymphoma}}		{{DISPLAYTITLE:Splenic marginal zone lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 10:		Line 11:

	==Primary Author(s)*==		==Primary Author(s)*==
			Madhu Pantrangi, Weill Cornell Medical Center

	*Snehal Patel, MD, PhD		Snehal Patel, MD, PhD

	==WHO Classification of Disease==		==WHO Classification of Disease==
Line 520:		Line 522:

	Prior Author(s):		Prior Author(s):

			Snehal Patel, MD, PhD

Bailey.Glen at 17:45, 24 March 2025

2025-03-24T17:45:55Z

← Older revision		Revision as of 12:45, 24 March 2025
Line 1:		Line 1:
	{{DISPLAYTITLE:Splenic marginal zone lymphoma}}		{{DISPLAYTITLE:Splenic marginal zone lymphoma}}

	[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]		[[HAEM5:Table_of_Contents\|Haematolymphoid Tumours (WHO Classification, 5th ed.)]]

Line 13:		Line 12:

	*Snehal Patel, MD, PhD		*Snehal Patel, MD, PhD
	~~__TOC__~~

	==WHO Classification of Disease==		==WHO Classification of Disease==

Bailey.Glen: Removed old template contents

2025-02-11T16:54:13Z

Removed old template contents

Show changes

Bailey.Glen at 19:01, 10 February 2025

2025-02-10T19:01:22Z

Show changes